LABIANA HEALTH S.A.EO-10 - Asset Resilience Ratio
LABIANA HEALTH S.A.EO-10 (8RK) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how LABIANA HEALTH S.A.EO-10's Asset Resilience Ratio has changed over time. See LABIANA HEALTH S.A.EO-10 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down LABIANA HEALTH S.A.EO-10's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see LABIANA HEALTH S.A.EO-10 stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €800.25 | 0.0% |
| Total Liquid Assets | €800.25 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: LABIANA HEALTH S.A.EO-10 maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
LABIANA HEALTH S.A.EO-10 Industry Peers by Asset Resilience Ratio
Compare LABIANA HEALTH S.A.EO-10's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621 |
Drug Manufacturers - Specialty & Generic | 2.04% |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
|
Jw Pharmac
KO:001060 |
Drug Manufacturers - Specialty & Generic | 3.65% |
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Samjin Pharm
KO:005500 |
Drug Manufacturers - Specialty & Generic | 0.25% |
Annual Asset Resilience Ratio for LABIANA HEALTH S.A.EO-10 (2021–2024)
The table below shows the annual Asset Resilience Ratio data for LABIANA HEALTH S.A.EO-10.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | €800.25 ≈ $935.58 |
€52.00 Million ≈ $60.80 Million |
-0.02pp |
| 2023-12-31 | 0.02% | €13.94K ≈ $16.30K |
€59.12 Million ≈ $69.12 Million |
+0.01pp |
| 2022-12-31 | 0.01% | €9.10K ≈ $10.64K |
€60.78 Million ≈ $71.06 Million |
0.00pp |
| 2021-12-31 | 0.02% | €11.45K ≈ $13.38K |
€68.37 Million ≈ $79.93 Million |
-- |
About LABIANA HEALTH S.A.EO-10
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, North America, rest of European Union, and internationally. The company offers anesthetics-sedative, anti-infective, anti-inflammatory, antiparasitic, hormonal, and nutritional products; metabolism regulators; and vitamin products. It also provides sterile, lyophilized dosage forms,… Read more